About Us

About ScitoVation

ScitoVation provides clients with the science, technical expertise and technology to understand how chemical compounds affect human health. Known for partnership, flexibility and proven success, we help clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products. We are recognized as industry experts in cell-based and computational methods who answer profound questions and provide leading-edge solutions for our clients.

ScitoVation is at the vanguard of our field, using experience, curiosity and energy to investigate complex issues, such as mode of action of a chemical, extrapolation of animal to human exposure, and the use of genetic expression and sequencing data to ascertain toxicity. Specifically, we have the innovative people and tools to: develop cutting edge customized cell-based assays to determine safety, model chemical disposition in the body, and analyze and interpret genetic data.

ScitoVation is made up of accomplished leaders in chemical safety. Our scientists pioneered the field of PBPK modeling for understanding chemical disposition and have been recognized by their peers for their contributions. Our team is continually acknowledged for their passion and results, and have received awards for lifetime achievement, best paper, and best presentation by the Society of Toxicology (SoT). We are frequently invited to present or participate in scientific conferences, including panels led by the National Academy of Sciences.


John Cline
President

John has more than 25 years as an executive leading life science and technology companies in the drug development and clinical space. In his role John is dedicated to ensuring that the company delivers the highest quality work to those that we serve. John has spent the last 20 years in his career as a classic entrepreneur. John founded one of the first commercially viable eclinical companies etrials. Along with a dedicated team they were able to successfully exit the business with the company becoming listed on the NASDAQ GM.

He has participated in over 500 clinical trial through etrials and other companies that he has had the good fortune to lead. In his role he assumes the responsibility for delivering operational excellence and is committed to maintaining the financial viability of ScitoVation. John is a graduate of the University of Georgia and has been awarded the INC 500 , The Ernst and Young Entrepreneur of the year finalist award and was named by PharmaVoice magazine as the top 100 most influential leaders in the pharmaceutical sector.

Rebecca Clewell
Chief Scientific Officer

Rebecca A. Clewell, Ph.D., boasts more than 15 years experience in developing in silico and in vitro models to inform chemical safety assessments. Dr. Clewell’s research program leverages expertise in cell culture, molecular biology, bioinformatics and computational biology to develop novel in vitro and computational tools to address key risk assessment issues without resorting to animal testing. These goals are accomplished through the development of fit-for-purpose in vitro assays that encompass the relevant human biology and are predictive of alterations of cellular signaling processes (toxicity pathways) that may lead to adversity. These assays also provide data for computational systems biology pathway models that quantitatively describe the underlying biology of cellular signaling pathways, as well as the mechanism and dose-dependence of chemical perturbation of these pathways. Together with in vitro-in vivo extrapolation (IV-IVE), these cell-based methods provide a point of departure for safety assessments based solely on biologically relevant in vitro data. Clewell received her Ph.D. in environmental science and engineering from the University of North Carolina at Chapel Hill. She has received awards from the Biological Modeling and Risk Assessment Specialty Sections of the Society of Toxicology and the Genetics and Mutagenesis Society. She has authored or co-authored more than 25 peer-reviewed journal articles, as well as several book chapters.

Miyoung Yoon
Director of Biokinetics and Biosimulations

Dr. Miyoung Yoon serves as Director of Biokinetics and Biosimulations and is leading the ScitoVation’s efforts to advance human health assessment by combining in vitro and computational tools to aid in interpretation of cell-based toxicity assay results and translate the findings into estimates of safe human exposure. She is an internationally recognized leader in quantitative in vitro to in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic modeling with special emphasis on addressing health risks in potentially sensitive populations such as infants and children. The current focus of her research is on incorporating metabolism and kinetics into the in vitro-based safety assessment process by improving the predictivity of in vitro metabolism systems and applying pharmacokinetic modeling tools for in vitro to in vivo extrapolation. Another area of her research interest is on utilizing the physiologically based pharmacokinetic modeling tool to evaluate the epidemiologically observed chemical-human health effects associations on the basis of human variability in kinetics.

Yoon is author or coauthor of more than 35 publications including peer-reviewed articles and book chapters. She received her Ph.D. in pharmacy from Seoul National University in South Korea. Recently, she has served as guest editor of the special issue of toxicology on the topic of quantitative in IVIVE: an essential element for in vitro-based risk assessment.

Patrick McMullen
Director of Computational Toxicology

Dr. Patrick McMullen, ScitoVation’s Director of Computational Toxicology, makes use of large datasets and mathematical modeling to address toxicology challenges. Dr. McMullen trained at Northwestern University where he developed tools at the intersection of molecular biology and chemical engineering. His specialty is leveraging high-content biological experiments (gene expression studies, high-throughput screens, imaging, and other sources) into a mechanistic understanding of the underlying biology. His data-driven approach to toxicology been instrumental in interpreting and communicating complex problems in diverse applications. Presently, McMullen’s focus is on understanding chemical mode of action using toxicogenomics and other tools. He is identifying and visualizing gene expression “fingerprints” that would allow high-throughput detection of chemical adversity.

Dr. McMullen manages a diverse computational biology team that uses modeling and high-content data to deepen our understanding of how chemicals interact with biological systems, including projects that support the chemical, consumer product, and pharmaceutical industries. Dr. McMullen currently serves on the National Academies of Sciences Emerging Science for Environmental Health Decisions Standing Committee and has over 20 peer-reviewed publications and book chapters to his name.

Harvey Clewell
Senior Scientist

Harvey Joseph Clewell III, Ph.D., DABTS, FATS, is a senior scientist with ScitoVation, located in Research Triangle Park, North Carolina. He has more than 40 years of experience in environmental quality research, toxicology research and chemical risk assessment. Dr. Clewell has gained an international reputation for his pioneering work in the application of physiologically based pharmacokinetic (PBPK) modeling to safety and risk assessment. He is also an expert in the use of cellular genomic response data to inform the mode of action for chemical toxicity and to determine alternative points of departure for risk assessments.

Clewell earned a Bachelor of Science in chemistry, graduating cum laude in 1969 from Bradley University in Peoria, Illinois; a Master of Arts in physical chemistry from Washington University in St. Louis, Missouri, in 1971; and a Ph.D. in toxicology from the University of Utrecht, the Netherlands, in 2007. He is a diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences, and holds the position of visiting scientist at the University of Utrecht in the Netherlands. He has authored more than 200 peer-reviewed scientific publications and a number of book chapters. In 2007, the Society of Toxicology recognized Clewell with the Arnold J. Lehman Award for major contributions to chemical safety and risk assessment.

 

Kevin Causey
Vice President of Business Development

Kevin Causey, MBA, has over 15 years of contract research organization business experience serving the pharmaceutical, chemical, and environmental science industry. He joined ScitoVation after serving nine years as Vice-President of Commercial Business Development for Integrated Laboratory Systems (ILS) and ILS Genomics. At ILS Kevin managed commercial sales efforts along with serving as a member of the corporate leadership team. During his time there he also participated in the acquisition and subsequent sale of the ILS Genomics business to LabCorp.

His current role includes managing sales, marketing, and business operations of ScitoVation to assure the successful growth and expansion of the company. Mr. Causey holds a B.S. in Biological Sciences from North Carolina State University, and an MBA from Pfeiffer University.